Related Experiment Videos
[Carbamazepine-induced aplastic anaemia: a case report]
J C Yáñez-Rubal1, J Estévez-Rodríguez, M C Crespo-López
1Servicio de Farmacia, Complejo Hospitalario Juan Canalejo, A Coruña, España. juan_carlos@canalejo.org
Revista De Neurologia
|October 22, 2002
Summary
Carbamazepine, a common neurological drug, can rarely cause fatal aplastic anemia. Early diagnosis and monitoring are crucial for managing this severe side effect.
Area of Science:
- Neurology
- Hematology
- Pharmacology
Background:
- Carbamazepine is widely used for neurological disorders.
- Aplastic anemia is a rare but serious side effect with high mortality.
- Understanding carbamazepine's side effect profile is critical.
Observation:
- A 51-year-old male developed aplastic anemia during carbamazepine treatment for brain injury.
- The patient presented with decreased platelets, progressing to medullar aplasia.
- Despite immunosuppressant therapy, the patient died 12 weeks later.
Findings:
- Aplastic anemia onset appears unrelated to age, disease, or carbamazepine dose.
- The typical onset is 3-4 months, with the first year being the highest risk period.
- Early diagnosis of aplastic anemia is essential for patient outcomes.
Implications:
- Treatment for aplastic anemia varies by age: bone marrow transplant for younger patients, immunosuppressants for older.
- Clinical judgment is key in determining the frequency of hematological monitoring.
- Patients and families must be educated on recognizing symptoms like infections or bruising.